Westfield reports 0 shares in Bicycle Therapeutics (NASDAQ: BCYC)
Westfield Capital Management Company, L.P. filed an Amendment No. 2 to a Schedule 13G, reporting that it beneficially owned 0 shares of Bicycle Therapeutics plc (NASDAQ: BCYC) common stock as of December 31, 2025. The filing indicates no voting or dispositive power held by Westfield for BCYC shares. The amendment was signed by Brandi McMahon, Vice President, Deputy Chief Compliance Officer, and dated March 3, 2026.
How this was made
The 30-second read
Why it matters
This update suggests no active investment or influence in BCYC, implying limited market impact.
Market read
The news has minimal relevance to the biotech or financial markets, given the lack of ownership change.
What to watch
The news may reflect portfolio rebalancing or passive investment strategies, not necessarily negative sentiment.
Background
Westfield Capital Management filed an amendment to its Schedule 13G, indicating it beneficially owns no shares of Bicycle Therapeutics as of December 31, 2025.
Ticker impact
Minimal impact due to zero ownership stake.
No significant price movement expected in BCYC stock.
The report explicitly states Westfield owns zero shares and holds no voting or dispositive power, indicating no direct influence or market signal.
Market effects
Limited, as the news does not affect Bicycle Therapeutics' operational outlook.
None expected.
Negligible.
Counterpoint
Some investors might interpret the zero ownership as a sign of strategic disengagement, potentially negative if perceived as lack of confidence.
Key entities
- Investment Management FirmWestfield Capital Management Company, L.P.
A major investment management firm that filed the amendment.
- Biotech CompanyBicycle Therapeutics plc
The subject of the filing, with no current ownership by Westfield.